Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526980 | 0.88 | HPGD (0.56) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6797131 | 0.84 | HPGD (0.54) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL4576597 | 0.82 | ALDH1A1 (0.63) | HPGDALDH1A1MAPTOPRD1OPRM1 | |
| SCHEMBL6796608 | 0.82 | OPRD1 (0.60) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL471665 | 0.80 | HPGD (0.72) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL1986972 | 0.78 | OPRD1 (0.62) | OPRD1OPRM1 | |
| SCHEMBL1934353 | 0.76 | OPRD1 (0.53) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL12360012 | 0.76 | OPRD1 (0.53) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6796353 | 0.74 | OPRD1 (0.79) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5703500 | 0.74 | HPGD (0.73) | HPGDMEN1LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138228-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1408037-A1 | Novel diarylmethylpiperazine and diarylmethylphenyl compounds with analgesic effect | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-6680321-B1 | 4-((1-PIPERAZINYLMETHYL)-BENZAMIDE DERIVATIVES; HYPOTENSIVE AGENTS; IMMUNOMODULATORS | ASTRAZENECA CANADA, INC. (CA) | 2004-01-20 | — | — | US | disclosed |
| US-6130222-A | Compounds with analgesic effect | ASTRA PHARMA INC. (CA) | 2000-10-10 | — | — | US | disclosed |
| EP-0915855-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138228-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | HPGD 517/4885MEN1 3913/4885LMNA 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.